Reviewer Disclosures

ReviewerEmploymentResearch GrantOther Research SupportSpeakers’ Bureau/HonorariaExpert WitnessOwnership InterestConsultant/Advisory BoardOther
Robert M. CareyUniversity of Virginia Health SystemNIHNoneNoneNoneNoneNoneNone
Gregory D. FinkMichigan State UniversityNIH (money paid to institution); AHA (money paid to institution); Medtronic*NoneNoneNoneNoneNoneNone
John M. FlackWayne State UniversityNIH*; Novartis*; Medtronic*NoneNovartisNoneNoneNovartis; NIH*; Medtronic*; Back Beat Hypertension*; NIVasc*None
Daniel W. JonesUniversity of MississippiNoneNoneNoneNoneNoneNoneNone
Janet WrightCDCNoneNoneNoneNoneNoneNoneNone
  • This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.